BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24276238)

  • 1. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
    Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
    Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
    Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
    Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
    Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
    Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling.
    Dow LE; Elsum IA; King CL; Kinross KM; Richardson HE; Humbert PO
    Oncogene; 2008 Oct; 27(46):5988-6001. PubMed ID: 18641685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetics and biology of KRAS in lung cancer.
    Westcott PM; To MD
    Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S; Ren X; Wang L; Zhang L; Wu X
    Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
    Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
    J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.
    Pearson HB; Perez-Mancera PA; Dow LE; Ryan A; Tennstedt P; Bogani D; Elsum I; Greenfield A; Tuveson DA; Simon R; Humbert PO
    J Clin Invest; 2011 Nov; 121(11):4257-67. PubMed ID: 21965329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
    Kim EY; Kim A; Kim SK; Chang YS
    Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
    Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
    Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
    Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.